With a career spanning over 40 years, including 38 years at Abbott/AbbVie, Poulos brings decades of success from a major ...
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
Hosted on MSN21h
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
Addresses the significant threat of antimicrobial resistance.
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Public health experts worry the FDA workforce will be slashed, impeding the ability of the agency to review new medicines ...
Hosted on MSN23h
These Stocks Missed on Earnings, But Will Rebound Next QuarterEarnings season is when investors get a progress report about the companies in their portfolio or on their watchlist. An earnings report is generally a lagging indicator. That’s because the headline ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks ...
AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback